Cimetidine, a histamine H2 receptor antagonist, occupies androgen receptors

J Clin Endocrinol Metab. 1979 Feb;48(2):189-91. doi: 10.1210/jcem-48-2-189.

Abstract

The histamine H2 receptor antagonist cimetidine is in increasing usage in the medical management of peptic ulcer. In clinical trials, its most frequent side effect is gynecomastia. Such estrogenic/antiandrogenic manifestations are well known side effects of treatment with digitoxin or spirolactones. Both of these drugs share a common skeleton with the steroid hormones and have been shown to occupy estrogen and/or androgen receptors. Cimetidine has no measurable affinity for rat uterine estradiol receptors, but competes for tritiated dihydrotestosterone-binding sites in mouse kidney preparations with a displacement curve parallel to that for unlabeled dihydrotestosterone. Steroid receptor-mediated side effects, therefore, may not be confined to molecules with a common skeleton, such as steroids, spirolactones, and cardiac glycosides, but may extend to such apparently unrelated molecules as histamine antagonists and androgens.

MeSH terms

  • Animals
  • Binding, Competitive
  • Cimetidine / metabolism*
  • Dihydrotestosterone / pharmacology
  • Female
  • Guanidines / metabolism*
  • Kidney / metabolism
  • Kinetics
  • Male
  • Mice
  • Receptors, Androgen / drug effects
  • Receptors, Androgen / metabolism*
  • Receptors, Estrogen / metabolism
  • Receptors, Histamine H2*
  • Receptors, Histamine*
  • Receptors, Steroid / metabolism*
  • Uterus / metabolism

Substances

  • Guanidines
  • Receptors, Androgen
  • Receptors, Estrogen
  • Receptors, Histamine
  • Receptors, Histamine H2
  • Receptors, Steroid
  • Dihydrotestosterone
  • Cimetidine